
Chinese biotechnology company founded at the end of 2012 by five returnee scientists and based in the Qiantang district of Hangzhou, Zhejiang, specialising in antibody drug conjugates. Develops linker and cytotoxic payload technologies with around fifty linker types and about a hundred payloads across the tubulysin, PBD, duocarmycin, amanitin and camptothecin classes, has filed more than five hundred patents, and runs over thirty ADC programmes of which six have reached the clinic, working with partners including Johnson & Johnson, Junshi Biosciences and WuXi Biologics.
회사 프로필 보기
평가 남기기